EGFR and non-small cell lung carcinoma: Of the included studies, four studies compared gefitinib plus chemotherapy vs. chemotherapy alone,[5, 15–17] two studies compared gefitinib alone vs. chemotherapy,[9, 18] and one study compared gefitinib plus best supportive care (BSC) vs. BSC alone.[19] Analysis of the efficacy of gefitinib in the Iressa NSCLC Trial Assessing Combination Treatment (INTACT-1)[15] and INTACT-2[5] studies based on EGFR expression, mutations, and gene amplification were also included.[6] Table 1 depicts the main characteristics of the included studies, whereas Table 2 shows the summary of the efficacy data.